Blinded and seeing the light, (John Noseworthy, Lou Gehrig and other tales of enlightenment)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients having serious neurological diseases often wonder why clinical trials must use controls and double blinding in order to prove efficacy. Studies on the effect of examiner blinding in multiple sclerosis trials, as well as the published results of an unblinded uncontrolled clinical trial of Vitamin E therapy in patients with amyotrophic lateral sclerosis (including Lou Gehrig) provide clear illustrations of the impact of blinding and controls on outcome. These reports serve as a resource for physicians, patients and their families in discussing the rationale for controls and double blinding, and instill caution that should be used when judging results of studies which are unblinded or uncontrolled.

Original languageEnglish
Pages (from-to)415-418
Number of pages4
JournalSeminars in Neurology
Volume18
Issue number3
StatePublished - 1998
Externally publishedYes

Fingerprint

Light
Clinical Trials
Amyotrophic Lateral Sclerosis
Vitamin E
Multiple Sclerosis
Physicians
Distance Counseling

Keywords

  • Amyotrophic lateral sclerosis
  • Clinical trials
  • Double blinding
  • Lou Gehrig
  • Multiple sclerosis
  • Noseworthy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Blinded and seeing the light, (John Noseworthy, Lou Gehrig and other tales of enlightenment). / Pascuzzi, Robert.

In: Seminars in Neurology, Vol. 18, No. 3, 1998, p. 415-418.

Research output: Contribution to journalArticle

@article{9828af7f27694691ae0247f3dbe8c2d9,
title = "Blinded and seeing the light, (John Noseworthy, Lou Gehrig and other tales of enlightenment)",
abstract = "Patients having serious neurological diseases often wonder why clinical trials must use controls and double blinding in order to prove efficacy. Studies on the effect of examiner blinding in multiple sclerosis trials, as well as the published results of an unblinded uncontrolled clinical trial of Vitamin E therapy in patients with amyotrophic lateral sclerosis (including Lou Gehrig) provide clear illustrations of the impact of blinding and controls on outcome. These reports serve as a resource for physicians, patients and their families in discussing the rationale for controls and double blinding, and instill caution that should be used when judging results of studies which are unblinded or uncontrolled.",
keywords = "Amyotrophic lateral sclerosis, Clinical trials, Double blinding, Lou Gehrig, Multiple sclerosis, Noseworthy",
author = "Robert Pascuzzi",
year = "1998",
language = "English",
volume = "18",
pages = "415--418",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Blinded and seeing the light, (John Noseworthy, Lou Gehrig and other tales of enlightenment)

AU - Pascuzzi, Robert

PY - 1998

Y1 - 1998

N2 - Patients having serious neurological diseases often wonder why clinical trials must use controls and double blinding in order to prove efficacy. Studies on the effect of examiner blinding in multiple sclerosis trials, as well as the published results of an unblinded uncontrolled clinical trial of Vitamin E therapy in patients with amyotrophic lateral sclerosis (including Lou Gehrig) provide clear illustrations of the impact of blinding and controls on outcome. These reports serve as a resource for physicians, patients and their families in discussing the rationale for controls and double blinding, and instill caution that should be used when judging results of studies which are unblinded or uncontrolled.

AB - Patients having serious neurological diseases often wonder why clinical trials must use controls and double blinding in order to prove efficacy. Studies on the effect of examiner blinding in multiple sclerosis trials, as well as the published results of an unblinded uncontrolled clinical trial of Vitamin E therapy in patients with amyotrophic lateral sclerosis (including Lou Gehrig) provide clear illustrations of the impact of blinding and controls on outcome. These reports serve as a resource for physicians, patients and their families in discussing the rationale for controls and double blinding, and instill caution that should be used when judging results of studies which are unblinded or uncontrolled.

KW - Amyotrophic lateral sclerosis

KW - Clinical trials

KW - Double blinding

KW - Lou Gehrig

KW - Multiple sclerosis

KW - Noseworthy

UR - http://www.scopus.com/inward/record.url?scp=0031796529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031796529&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 415

EP - 418

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 3

ER -